Melatonin and clinical application

Reproduction Nutrition Development

Volumn 39, Issue 3, 1999, Pages 367-382

  Wetterberg, Lennart ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Circadian; Clinics; Depression; Melatonin; Sleep

Indexed keywords

MELATONIN;

AGING; CIRCADIAN RHYTHM; CLINICAL FEATURE; CONFERENCE PAPER; DEPRESSION; HUMAN; JET LAG; MENTAL DISEASE; SKIN PROTECTION; SLEEP DISORDER; SURGERY;

EID: 0033389698     PISSN: 09265287     EISSN: None     Source Type: Journal    
DOI: 10.1051/rnd:19990309     Document Type: Conference Paper

References (70)

1. Al-Ghoul W.M., Herman M.D., Dubocovich M.L., Melatonin receptor subtype expression in human cerebellum, Neuroreport 9 (1998) 4063-4068.
2. Aoki H., Yamada N., Ozeki Y., Yamane H., Kato N., Minimum light intensity required to suppress nocturnal melatonin concentration in human saliva, Neurosci. Lett. 252 (1998) 91-44.
3. Arendt J., Complex effects of melatonin, Therapy 53 (1998) 479-488.
4. Arendt J., Skene DJ., Middleton B., Lockley S.W., Deacon S., Efficacy of melatonin treatment in jet lag, shift work, and blindness, J. Biol. Rhythms 12 (1997) 604-617.
5. Asplund R., Aherg H., Wetterberg L., The seasonal interrelationship between melatonin, vasopressin, and serum osmolality in elderly subjects, J. Pineal Res. 25 (1998) 67-72.
6. Barnes R.G., Forbes M.J., Arendt J., Shift type and season affect adaptation of the 6-sulphatoxymelatonin rhythm in offshore oil rig workers, Neurosci. Lett. 252 (1998) 179-182.
7. Bergstrom W.H., Hakanson D.O., Melatonin: the dark force. Adv. Pediatr. 45 (1998) 91-106.
8. Brainard G.C., Kavet R., Kheifets L.I., The relationship between electromagnetic field and light exposures to melatonin and breast cancer risk: a review of the relevant literature, J. Pineal Res. 26 (1999) 65-100.
9. Brusco L.I., Marquez M., Cardinali D.P., Monozygotic twins with Alzheimer's disease treated with melatonin: Case report, J. Pineal Res. 25 (1998) 260-263.
10. Bubenik G.A., Blask D.E., Brown G.M., Maestroni G.J., Pang S.F., Reiter R.J., Viswanathan M., Zisapel N., Prospects of the clinical utilization of melatonin, Biol. Signals Recept. 7 (1998) 195-219.
11. Cajochen C., Krauchi K., Danilenko K.V., Wirz-Justice A., Evening administration of melatonin and bright light: interactions on the EEG during sleep and wakefulness, J. Sleep Res. 7 (1998) 145-157.
12. Ciesla W., Can high maternal melatonin concentrations be responsible for inducing fetal pathologies, and can melatonin participate in immunohormonal homeostasis by determining prohormone convertase activity? Hypothesis and facts, Med. Hypotheses 51 (1998) 269-280.
13. Costa A., Leston J.A., Cavallini A., Nappi G., Cluster headache and periodic affective illness: common chronobiological features, Funct. Neurol. 13 (1998) 263-272.
14. Dolberg O.T., Hirschmann S., Grunhaus L., Melatonin for the treatment of sleep disturbances in major depressive disorder. Am. J. Psychiatry 155 (1998) 1119-1121.
15. Dreher F., Gabard B., Schwindt D.A., Maibach H.I., Topical melatonin in combination with vitamins E and C protects skin from ultraviolet-induced erythema: a human study in vivo, Br. J. Dermatol. 139 (1998) 332-339.
16. Fjaerli O., Lund T., Osterud B., The effect of melatonin on cellular activation processes in human blood, J. Pineal Res. 26 (1999) 50-55.
17. Garcia-Maurino S., Gonzalez-Haba M.G., Calvo J.R., Goberna R., Guerrero J.M., Involvement of nuclear binding sites for melatonin in the regulation of IL-2 and IL-6 production by human blood mononuclear cells, J. Neuroimmunol. 92 (1998) 76-84.
18. Gubitz A.K., Reppert S.M., Assignment of the melatonin-related receptor to human chromosome X (GPR50) and mouse chromosome X, Genomics 55 (1999) 248-251.
19. Jean-Louis G., von Gizycki H., Zizi F., Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment, J. Pineal Res. 25 (1998) 177-183.
20. Kadva A, Djahanbakhch O., Monson J., Di WL., Silman R., Elevated nocturnal melatonin is a consequence of gonadotropin-releasing hormone deficiency in women with hypothalamic amenorrhea, J. Clin. Endocrinol. Metab. 83 (1998) 3653-3662.
21. Karasek M., Woldanska-Okonska M., Crernicki J., Zylinska K., Swietoslawski J., Chronic exposure to 2.9 mT, 40 Hz magnetic field reduces melatonin concentrations in humans, J. Pineal Res. 25 (1998) 240-244.
22. Kendler B.S., Melatonin: media hype or therapeutic breakthrough?, Nurse Pract. 22 (1997) 66-77.
23. Kunz D., Bes F., Schlattmann P., Hermann W.M., On pineal calcification and its relation to subjective sleep perception: a hypothesis-driven pilot study, Psychiatry Res. 30 (1998) 187-191.
24. Lasko T.A., Kripke D.F., Elliot J.A., Melatonin suppression by illumination of upper and lower visual fields, J. Biol. Rhythms 14 (1999) 122-125.
25. Lewy A.J., The dim light melatonin onset, melatonin assays and biological rhythm research in humans, Biol. Signals Pecept. 8 (1999) 79-83.
26. Lewy A.J., Ahmed S., Latham-Jackson J.M., Sack R.L., Melatonin shifts human circadian rhythms according to a phase-response curve, Chronobiol. Int. 9 (1992) 380-392.
27. Lewy A.J., Bauer V.K., Cutler N.L., Sack R.L., Ahmed S., Thomas K.H., Blood M.L., Jackson J.M., Morning vs evening light treatment of patients with winter depression, Arch. Gen. Psychiatry 55 (1998) 890-896.
28. Li X., Borjigin J., Snyder S.H., Molecular rhythms in the pineal gland, Curr. Opin. Neurobiol. 8 (1998) 648-651.
29. Liu R.Y., Zhou J.N., van Heerikhuize J., Hofman M.A., Swaab D.F., Decreased melatonin levels in postmortem cerebrospinal fluid in relation to ageing, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype, J. Clin. Endocrinol. Metab. 84 (1999) 323-327.
30. Lockley S.W., Skene D.J., Thapan K., English J., Ribeiro D., Haimov I., Hampton S., Middleton B., von Schantz M., Arendt J., Extraocular light exposure does not suppress plasma melatonin in humans, J. Clin. Endocrinol. Metab. 83 (1998) 3369-3372.
31. Luboshitzky R., Yanai D., Shen-Orr Z., Israeli E., Herer P., Lavie P., Daily and seasonal variations in the concentration of melatonin in the human pineal gland, Brain Res. Bull. 47 (1998) 271-276.
32. Mayeda A., Mannon S., Hofstetter J., Adkins M., Baker R., Hu K., Nurnberger J. Jr, Effects of indirect light and propranolol on melatonin levels in normal human subjects. Psychiatry Res. 81 (1998) 9-17.
33. Miles A., Philbrick D.R., Melatonin and psychiatry, Biol. Psychiatry 23 (1998) 405-425.
34. Millet B., Touitou Y., Poirier M.F., Bourdel M.C., Hantouche E., Bogdan A., Olic J.P., Plasma melatonin and cortisol in patients with obsessive-compulsive disorder: relationship with axillary temperature, physical activity, and clinical symptoms, Biol. Psychiatry 44 (1998) 874-881.
35. Monteleone P., Natale M., La Rocca A., Maj M., Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics, Neuropsychobiology 36 (1997) 159-163.
36. Mullen P.E., Silman R.E., The pineal and psychiatry: a review, Psychol. Med. 7 (1997) 407-417.
37. Nishimura S., Fujino Y., Shimaoka M., Hagihira S., Taenaka N., Yoshiya I., Circadian secretion patterns of melatonin after major surgery, J. Pineal Res. 25 (1998) 73-77.
38. Nonno R., Fraschini F., Stankov B.M., Methods for the evaluation of drug action at the human melatonin receptor subtypes, Biol. Signals Recept. 8 (1999) 32-40.
39. Palm L., Blennow G., Welterberg L., Long-term melatonin treatment in blind children and young adults with circadian sleep-wake disturbances. Dev. Med. Child Neurol. 39 (1997) 319-325.
40. Partonen T., Extrapineal melatonin and exogenous serotonin in seasonal affective disorder. Med. Hypotheses 51 (1998) 441-442.
41. Pillar G., Etzioni A., Shahar E., Lavie P., Melatonin treatment in an institutionalised child with psychomotor retardation and an irregular sleepwake pattern, Arch. Dis. Child 79 (1998) 63-64.
42. Poirier M.F., Current trends in clinical psychiatric research. Presse Med. 19 (1998) 2185-2189.
43. Rasmussen D.D.. Boldt B.M., Wilkinson C.W., Yellon S.M., Matsumoto A.M., Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels, Endocrinology 140 (1999) 1009-1012.
44. Reber A., Huber P.R., Ummenhofer W., Gurtler C.M., Zurschmiede C., Drewe J., Schneider M., General anaesthesia for surgery can influence circulating melatonin during daylight hours, Acta Anaesthesiol. Scand. 42 (1998) 1050-1056.
45. Reiter R.J., Oxidative damage in the central nervous system: protection by melatonin, Prog. Neurobiol. 56 (1998) 359-384.
46. Reiter R.J., Maestroni G.J., Melatonin in relation to the antioxidative defense and immune systems: possible implications for cell and organ transplantation, J. Mol. Med. 77 (1999) 36-39.
47. Rodenbeck A., Huether G., Ruther E., Hajak G., Altered circadian melatonin secretion patterns in relation to sleep in patients with chronic sleepwake rhythm disorders, J. Pineal Res. 25 (1998) 201-210.
48. Shafii M., Shafii S.L., Melatonin in Psychiatric and Neoplasyic Disorders, Am. Psych. Press, Inc., Washington, 1998.
49. Slotten H.A., Krekling S., Does melatonin have an effect on cognitive performance?, Psychoneuroendocrinology 21 (1996) 673-680.
50. Stevens R.G., Wilson B.W., Anderson L.E., The Melatonin Hypothesis; Breast Cancer and the Use of Electric Power, Battelle Press, Columbus, 1997
51. Suhner A., Schlagenhauf P., Johnson R., Tschopp A., Steffen R., Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag, Chronohiol. Int. 15 (1998) 655-666.
52. Suhner A., Schlagenhauf P., Tschopp A., Hauri-Bionda R., Friedrich-Koch A., Steffen R., Impact of melatonin on driving performance, J. Travel Med. 5 (1998) 7-13.
53. Tan D.X., Manchester L.C., Reiter R.J., Plummer B.F., Hardies L.J., Weintraub S.T., Vijayalaxmi., Shepherd A.M., A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation, Biochem. Biophys. Res. Commun. 253 (1998) 614-620.
54. Thalén B.E., Kjellman B.F., Morkrid L., Wetterberg L., Melatonin in light treatment of patients with seasonal and nonseasonal depression, Acta Psychiatr. Scand. 92 (1995) 274-284.
55. Thalén B.E., Morkrid L., Kjellman B.F., Wetterberg L., Cortisol in light treatment of seasonal and non-seasonal depression: relationship between melatonin and cortisol, Acta Psychiatr. Scand. 96 (1997) 385-394.
56. Thomas L., Drew J.E., Abramovich D.R., Williams L.M., The role of melatonin in the human fetus (review), Int. J. Mol. Med. 1 (1998) 539-543.
57. Touitou Y., Melatonin: hormone and medication, C. R. Seances Soc. Biol. Fil. 192 (1998) 643-657.
58. Van Cauter E., Putative roles of melatonin in glucose regulation. Therapie 53 (1998) 467-472.
59. Visser E.K., Beersma D.G., Daan S., Melatonin suppression by light in humans is maximal when the nasal part of the retina is illuminated, J. Biol. Rhythms 14 (1999) 116-121.
60. Vondrasova-Jelinkova D., Hajek I., Illnerova H., Adjustment of the human melatonin and cortisol rhythms to shortening of the natural summer photoperiod, Brain Res. 816 (1999) 249-253.
61. Wahlund B., Grahn H., Saaf J., Wetterberg L., Affective disorder subtyped by psychomotor symptoms, monoamine oxidase, melatonin and cortisol: identification of patients with latent bipolar disorder, Eur. Arch. Psychiatry Clin. Neurosci. 248 (1998) 215-224.
62. Wahlund B., Saaf J., Grahn H., Wetterberg L., Diagnostic subgrouping of depressed patients by principal component analysis and visualised pattern recognition, Psychiatry Res. 81 (1998) 393-401.
63. Waldhauser F., Kovacs J., Reiter E., Age-related changes in melatonin levels in humans and its potential consequences for sleep disorders, Exp. Gerontol. 33 (1998) 759-772.
64. Webb S.M., Puig-Domingo M., Moller M., Pévet P., Pineal Update: From Molecular Mechanisms to Clinical Implications, PJD Publications Ltd. Westbury, NY, USA, 1997.
65. Wetterberg L., Melatonin and affective disorders, Ciba Found. Symp. 117 (1985) 253-265.
66. Wetterberg L., Bergiannaki J.D., Papanigopoulos T., von Knorring L., Eberhard G., Bratlid T., Yuwiler A., Normative melatonin excretion: a multinational study. Psychoneuroendocrinology 24 (1999) 209-226.
67. Weydahl A., Sothern R.B., Welterberg L., Seasonal variations in melatonin may modulate glycemic response to exercise. Percept. Mol. Skills 86 (1998) 1061-1062.
68. Wikner J., Svanborg E., Wetterberg L., Rojdmark S., Melatonin secretion and excretion in patients with obstructive sleep apnea syndrome, Sleep 20 (1997) 1002-1007.
69. Wikner J., Wetterberg L., Rojdmark S., Does hypercalcaemia or calcium antagonism affect human melatonin secretion or renal excretion?, Eur. J. Clin. Invest. 27 (1997) 374-379.
70. Wikner J., Hirsch U., Wetterberg L., Rojdmark S., Fibromyalgia - a syndrome associated with decreased nocturnal melatonin secretion, Clin. Endocrinol. (Oxf) 49 (1998) 179-183.